

**MISSISSIPPI DIVISION OF MEDICAID  
DRUG UTILIZATION REVIEW (DUR) BOARD  
MINUTES OF THE DECEMBER 3, 2020 MEETING**

<b>DUR Board Roster: State Fiscal Year 2020* (July 1, 2019- December 31,2020)</b>	<b>Mar 2020</b>	<b>Jun 2020</b>	<b>Sep 2020</b>	<b>Dec 2020</b>
Lauren Bloodworth, PharmD (Chair)	✓	✓	✓	✓
Rhonda Dunaway, RPh		✓	✓	✓
Tanya Fitts, MD	✓	✓	✓	✓
Ray Montalvo, MD	✓	✓	✓	✓
Holly Moore, PharmD	✓	✓	✓	
Janet Ricks, DO	✓	✓	✓	
Cheryl Sudduth, RPh		✓		✓
James Taylor, PharmD	✓	✓	✓	✓
Alan Torrey, MD	✓	✓		✓
<b>TOTAL PRESENT**</b>	<b>9</b>	<b>11</b>	<b>9</b>	<b>7</b>

\* DUR Board Member Terms extended through December 31, 2020

\*\* Total Present may not be reflected by individual members marked as present above due to members who either resigned or whose terms expired being removed from the list.

**Also Present:**

**Division of Medicaid (DOM) Staff:**

Terri Kirby, RPh, CPM, Pharmacy Director; Dennis Smith, RPh, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Chris Yount, MA, PMP, Staff Officer – Pharmacy;

**University of Mississippi School of Pharmacy - MS-DUR Staff:**

Eric Pittman, PharmD, MS-DUR Project Director; Kaustuv Bhattacharya, PhD, Research Assistant Professor - CPM;M;

**Conduent Staff:**

Lew Anne Snow, RN, BSN, Pharmacy Services Sr. Analyst, Mississippi Medicaid Project; Leslie Leon, PharmD, Clinical Pharmacist, Mississippi Medicaid Project;

**Change Healthcare Staff:**

Paige Clayton, PharmD, On-Site Clinical Pharmacist; Sarah Boydston, PharmD, PA Pharmacist;

**Alliant Health Staff:**

Catherine Brett, MD, Medical Director;

**Coordinated Care Organization (CCO) Staff:**

Heather Odem, PharmD, Director of Pharmacy - Mississippi, UnitedHealthcare Community & State; Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health;

**Visitors:**

Kimberly Clark, Viiv Healthcare; David Condrick, BridgeBio; Brandon Cope, Otsuka; Bryan Dillon, Otsuka; Jill Gran, Otsuka; Julie Hardie, Novo Nordisk; Phil Hecht, Abbvie; Evelyn Johnson, Capital Resources; Bryan Leibowitz, Takeda; Nole Mangine, Allergan; Beau Pender, Otsuka; Mick Peoples, Eli Lilly; Kenneth Irvin Riddle, Braeburn; Michelle Shirley, Indivior; Justin Simmons, Abbvie; Mary Stoots, Artia Solutions; Jason Swartz, Otsuka; Bruce Wallace, Azurity; Gene Wingo, Biogen; Kim Wolak, Clark; Brent Yount, GBT.

**Call to Order:**

Dr. Pittman called the meeting to order at 1:02pm and welcomed everyone to the meeting via Zoom.

**OLD BUSINESS:**

Dr. Bloodworth moved to approve the minutes from the September 2020 DUR Board Meeting, seconded by Dr. Fitts, and unanimously approved by the DUR Board.

**Resource Utilization Review:**

Dr. Pittman presented the resource utilization report for July 2020 – September 2020. Enrollment numbers continued to climb since April 2020 with 6.4% more beneficiaries receiving pharmacy benefits compared to September 2019. While enrollment numbers increased, the number of prescription fills decreased compared to September 2019. The total dollars paid for prescriptions was approximately equal to that for the same period in 2019.

**Feedback and Discussion from Board:**

No follow-up discussion concerning previous DUR Board topics was held.

## **NEW BUSINESS:**

### **Update on MS-DUR Educational Interventions:**

Dr. Pittman provided an overview of all DUR mailings that occurred September 2020 – November 2020.

### **Special Analysis Projects:**

#### ***Adult and Child Core Set Quality Measures***

Dr. Catherine Brett provided an overview to the Board describing quality measures and Medicaid's continued work to improve care provided to beneficiaries. Following Dr. Brett's presentation, Dr. Pittman reviewed the adult and child core set measures MS-DUR ran for CY 2019. For each measure, Dr. Pittman provided a brief description of the measure, performance reported, and comparative national data, when available.

*No action was taken on items from this report.*

#### ***Naloxone Use in High Risk Beneficiaries***

Dr. Pittman provided a report describing the use of naloxone among beneficiaries at high risk of experiencing adverse opioid events or overdose. This report was the result of a request from the Board at the September 2020 DUR Board Meeting. The analysis revealed that among Medicaid beneficiaries identified as high risk, less than 2% had a naloxone claim. The board discussed various methods for increasing naloxone use among beneficiaries at high risk of overdose events. Following a robust discussion, the following recommendation was considered:

1. DOM should distribute educational reminders to prescribers and pharmacists regarding the FDA's recent recommendation for naloxone, the covered status of naloxone products on the Preferred Drug List, and the Mississippi State Department of Health's Naloxone Standing Order.

*Dr. Torrey motioned to approve the recommendation, seconded by Dr. Bloodworth, and unanimously approved by the Board.*

#### ***Adult Vaccines***

Dr. Pittman reviewed a report on the administration of adult vaccines to Medicaid beneficiaries during calendar year 2019. DOM is seeking approval from CMS to expand adult vaccine services offered through pharmacies. The report detailed adult vaccination rates overall and highlighted opportunities for increasing vaccination rates through the pharmacy benefit. The following recommendation was considered:

1. Upon CMS approval of the Vaccine State Plan Amendment (SPA), DOM should begin an educational initiative targeting pharmacists. The education should highlight the expanded opportunities granted pharmacists through the updated SPA and serve as a call to action for pharmacists to actively engage in adult immunizations.

*Dr. Fitts motioned to approve the recommendation, seconded by Ms. Dunaway, and unanimously approved by the board.*

**FDA Drug Safety Updates:**

Dr. Pittman presented FDA drug safety communications for September 2020 – November 2020.

**Pharmacy Program Update:**

Ms. Kirby provided the Board with the following Pharmacy Program Updates:

1. Dennis Smith was officially welcomed as the new DUR Coordinator in the Office of Pharmacy.
2. DOM is in the process of changing to a new fiscal agent, Gainwell (formerly known as DXC). This change will occur in 2022.

**Miscellaneous:**

**2021 Meeting Dates/Times**

March 4, 2021

June 10, 2021

September 16, 2021

December 9, 2021

*\*Meeting time will remain at 1 pm.*

**Next Meeting Information:**

Dr. Pittman announced that the next meeting of the DUR Board will take place on March 4, 2021 at 1pm.

*Dr. Bloodworth motioned to adjourn the meeting at 2:19 pm, seconded by Ms. Dunaway, and unanimously approved by the Board.*

Submitted,

Eric Pittman, PharmD  
Evidence-Based DUR Initiative, MS-DUR

**Meeting Location:** Woolfolk Building, 501 North West Street, Virtual Meeting, Jackson, MS 39201

**Contact Information:** Office of Pharmacy:

Chris Yount, 601-359-5253; [Christopher.yount@medicaid.ms.gov](mailto:Christopher.yount@medicaid.ms.gov), or  
Jessica Tyson, 601-359-5253; [Jessica.Tyson@medicaid.ms.gov](mailto:Jessica.Tyson@medicaid.ms.gov)

Notice details:

**State Agency:** MS Division of Medicaid

**Public Body:** Drug Utilization Board (DUR) Meeting

**Subject:** Quarterly Meeting

**Date and Time:** March 19, 2020; June 11, 2020; September 17, 2020; and December 3, 2020 at 1PM

**Description:** The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.

### December 3, 2020 DUR Board Meeting – Update

The December 3, 2020 Drug Utilization Review (DUR) Board Meeting will take place virtually beginning at 1pm. Link information will be posted the day before or day of the meeting at this page. Participants are reminded to join the meeting at least 15 minutes prior to meeting time. Registration will end once the meeting begins.

**Meeting information:**

<https://zoom.us/j/96370462198?pwd=ZGY0UUIZNFVtJlVZFpUjVVOOEIpZz09>

**Meeting ID:** 963 7046 2198 **Passcode:** 036569 **Phone:** 929-436-2866/301-715-8592

As a reminder, when joining the virtual meeting, please register with your first and last name as well as the company/organization which you are representing. When in Zoom meetings, this can be done using the "rename" function. If you are dialing in via phone and computer, please remember to mute your computer and microphone to limit feedback.

Meeting agenda and packet information is posted in the table below.